Atea Pharmaceuticals, Inc. Common Stock (AVIR) is a publicly traded Healthcare sector company. As of May 21, 2026, AVIR trades at $4.18 with a market cap of $331.31M and a P/E ratio of -2.15. AVIR moved +0.96% today. Year to date, AVIR is +22.87%; over the trailing twelve months it is +44.48%. Its 52-week range spans $2.46 to $6.45. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces AVIR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Atea to Showcase Bemnifosbuvir-Ruzasvir and AT-587 Data at EASL Congress: Atea Pharmaceuticals will present three abstracts at the EASL Congress May 27–30 on its bemnifosbuvir-ruzasvir fixed-dose HCV regimen and top-poster preclinical data for AT-587 HEV inhibitor. It expects topline results from Phase 3 C-BEYOND and C-FORWARD and will advance AT-587 into clinical studies mid-year.
| Metric | Value |
|---|---|
| Price | $4.18 |
| Market Cap | $331.31M |
| P/E Ratio | -2.15 |
| EPS | $-1.94 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.45 |
| 52-Week Low | $2.46 |
| Volume | 9.11K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-158.35M |
| Gross Margin | 0.00% |
3 analysts cover AVIR: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.